Cytokines in the management of high risk or advanced breast cancer: An update and expectation

Current Cancer Drug Targets

Volumn 9, Issue 8, 2009, Pages 888-903

  Carpi, A ^a   Nicolini, A ^a   Antonelli, A ^a   Ferrari, P ^a   Rossi, G ^b  

^a UNIVERSITY OF PISA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Advanced breast cancer; Cytokines

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIESTROGEN; BETA INTERFERON; CYCLOSPORIN; EPIRUBICIN; ESTROGEN RECEPTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 6; LETROZOLE; MEDROXYPROGESTERONE; MELATONIN; PACLITAXEL; RETINOIC ACID; RETINOL PALMITATE; TAMOXIFEN; TOREMIFENE; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER RISK; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG MEGADOSE; FLU LIKE SYNDROME; HUMAN; HYPOTENSION; IMMUNE SYSTEM; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; LOW DRUG DOSE; MELANOMA; MENOPAUSAL SYNDROME; METASTASIS; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; POSTMENOPAUSE; RECURRENT CANCER; REVIEW; SIDE EFFECT; SKIN METASTASIS; SOFT TISSUE METASTASIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; INTERLEUKIN-2; TREATMENT OUTCOME;

EID: 74849121785     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800909790192392     Document Type: Review

References (194)

1. Nicolini, A.; Carpi, A.; Rossi, G. Cytokines in breast cancer. Cytokines Growth Factor Rev. 2006, 17, 325-337.
2. Pantschenko, A. G.; Pushkar, I.; Anderson, K. H.; Wang, Y.; Miller, L. J.; Kurtzman, S. H.; Barrows, G.; Kreutzer, D. L. The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int. J. Oncol. 2003, 23, 269-284.
3. Singer, C. F.; Kronsteiner, N.; Hudelist, G.; Marton, E.; Walter, I.; Kubista, M.; Czerwenka, K.; Schreiber, M.; Seifert, M.; Kubista, E. Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype. Clin. Cancer Res. 2003, 9, 4877-4883.
4. Strieter, R. M.; Burdick, M. D.; Mestas, J.; Gomperts, B.; Keane, M. P.; Belperio, J. A. Cancer CXC chemokine networks and tumour angiogenesis. Eur. J. Cancer 2006, 42, 768-778.
5. Snoussi, K.; Mahfoudh, W.; Bouaouina, N.; Ahmed, S. B.; Helal, A. N.; Chouchane, L. Genetic variation in IL-8 associated with increased risk and poor prognosis of breast carcinoma. Hum. Immunol. 2006, 67, 13-21.
6. Yao, C.; Lin, Y.; Chua, M. S.; Ye, C. S.; Bi, J.; Li, W.; Zhu, Y. F.; Wang, S. M. Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int. J. Cancer 2007, 12, 1949-1957.
7. Singh, B.; Berry, J. A.; Vincent, L. E.; Lucci, A. Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer. J. Surg. Res. 2006, 134, 44-51.
8. Hanavadi, S.; Martin, T. A.; Watkins, G.; Mansel, R. E.; Jiang, W. G. Expression of interleukin 11 and its receptor and their prognostic value in human breast cancer. Ann. Surg. Oncol. 2006, 13, 802-808.
9. Aspord, C.; Pedroza-Gonzalez, A.; Gallegos, M.; Tindle, S.; Burton, E. C.; Su, D.; Marches, F.; Banchereau, J.; Palucka, A. K. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J. Exp. Med. 2007, 204, 1037-1047.
10. Abbas, A. K. Cytokines. In Cellular and Molecular Immunology; Lichtmen, A. H. Ed.; 5th edition, chapter 11th, Elsevier Publisher: 2005, pp. 252-279.
11. Wang, T.; Niu, G.; Kortylewski, M.; Burdelya, L.; Shain, K.; Zhang, S; Bhattacharya, R.; Gabrilovich, D.; Heller, R.; Coppola, D.; Dalton, W.; Jove, R.; Pardoll, D.; Yu, H. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 2004, 10, 48-54.
12. Sato, T.; McCue, P.; Masuoka, K.; Salwen, S.; Lattime, E. C.; Mastrangelo, M. J.; Berd, D. Interleukin 10 production by human melanoma. Clin. Cancer Res. 1996, 2, 1383-1390.
13. Nicolini, A.; Carpi, A.; Rossi, G. Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. Cancer Lett. 2007, 251, 330-338.
14. Poindexter, N. J.; Sahin, A.; Hunt, K. K.; Grimm, E. A. Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res. 2004, 6, R408-415.
15. Kim, Y. S.; Jung, H. W.; Choi, J.; Kwon, B. S.; Ham, S. Y.; Jung, A. K.; Ko, B. K. Expression of AITR and AITR ligand in breast cancer patients. Oncol. Rep. 2007, 18, 1189-1194.
16. Liang, M.; Zhang, P.; Fu, J. Up-regulation of LOX-1 expression by TNF-alpha promotes trans-endothelial migration of MDA-MB-231 breast cancer cells. Cancer Lett. 2007, 258, 31-37.
17. Hinshelwood, R. A.; Huschtscha, L. I.; Melki, J.; Stirzaker, C.; Abdipranoto, A.; Vissel, B.; Ravasi, T.; Wells, C. A.; Hume, D. A.; Reddel, R. R.; Clark, S. J. Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis. Cancer Res. 2007, 67, 11517-11527.
18. Gadir, N.; Lee, E.; Garcia, A.; Toschi, A.; Foster, D. A. Suppression of TGF-beta signaling by phospholipase. D. Cell Cycle 2007, 6, 2840-2845.
19. Tang, B.; Yoo, N.; Vu, M.; Mamura, M.; Nam, J. S.; Ooshima, A.; Du, Z.; Desprez, P. Y.; Anver, M. R.; Michalowska, A. M.; Shih, J.; Parks, W. T.; Wakefield, L. M. Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res. 2007, 67, 8643-8652.
20. Maemura, M.; Iino, Y.; Horiguchi, J.; Takei, H.; Horii, Y.; Koibuchi, Y.; Yokoe, T.; Takeyoshi, I.; Ohwada, S.; Morishita, S. Effects of interferon-alpha on cellular proliferation and adhesion of breast carcinoma cells. Oncol. Rep. 1999, 6, 5575-5561.
21. Martin, J. H.; Symonds, A. Synergistic antitumour effect of a combination of toremifene and interferon-alpha on ZR-75-1 human breast cancer cells: dependence on interferon-alpha subtype. Oncol. Rep. 2002, 9, 379-382.
22. Kang, J. X.; Liu, J.; Wang, J.; He, C.; Li, F. P. The extract of huanglian, a medicinal herb, induces cell growth arrest and apoptosis by upregulation of interferon-{beta} and TNF-{alpha} in human breast cancer cells. Carcinogenesis 2005, 26, 1934-1939.
23. Connet, J. M.; Bradi, L.; Giordano, T. J.; Connet, W. C.; Doherty, G. M. Interferon regulatory factor 1 (IRF-1) and IRF-2 expression in breast cancer tissue microarrays. J. Interferon Cytokine Res. 2005, 25, 587-594.
24. Bouker, K. B.; Skaar, T. C.; Riggins, R. B.; Harburger, D. S.; Fernandez, D. R.; Zwart, A.; Wang, A.; Clarke, R. Interferon regulatory factor-1 (IRF-1) exhibits tumour suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis 2005, 26, 1527-1535.
25. Kim, P. K.; Armstrong, M.; Liu, Y.; Yan, P.; Bucher, B.; Zuckerbraun, B. S.; Gambotto, A.; Billiar, T. R.; Yim, J. H. IRF-1 expression induces apoptosis and inhibits tumour growth in mouse mammary cancer cells in vitro and in vivo. Oncogene 2004, 23, 1125-1135.
26. Belardelli, F.; Ferrantini, M.; Proietti, E.; Kirkwood, J. M. Interferon-alpha in tumour immunity and immunotherapy. Cytokine Growth Factor Rev. 2002, 13, 119-134.
27. Recchia, F.; Frati, L.; Rea, S.; Torchio, P.; Sica, G. Minimal residual disease in metastatic breast cancer: treatment with IFN-beta, retinoids, and tamoxifen. J. Interferon Cytokine Res. 1998, 18, 41-47.
28. Bouker, K. B.; Skaar, T. C.; Fernandez, D. R.; O'Brien, K. A.; Riggins, R. B.; Cao, D.; Clarke, R. Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182, 780 (faslodex, fulvestrant). Cancer Res. 2004, 64, 4030-4039.
29. Clarke, N.; Jimenez-Lara, A. M.; Voltz, E.; Gronemeyer, H. Tumour suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J. 2004, 23, 3051-3060.
30. Danforth, D. N.; Zhu, Y. Conversion of Fas-resistant to Fassensitive MCF-7 Breast Cancer Cells by the Synergistic Interaction of Interferon-gamma and all-TransRetinoic Acid. Breast Cancer Res. Treat. 2005, 94, 81-91.
31. Morgan, D. A.; Ruscetti, F. W.; Gallo, R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976, 193, 1007-1008.
32. Swain, S. L. Lymphokines and the immune response: the central role of IL-2. Curr. Opin. Immunol. 1991, 3, 304-310.
33. Lindner, D. J.; Borden, E. C. Effects of tamoxifen and interferonbeta or the combination on tumor-induced angiogenesis. Int. J. Cancer 1997, 71, 456-461.
34. Fehniger, T. A.; Cooper, M. A.; Caligiuri, M. A. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev. 2002, 13, 169-183.
35. Honma, S.; Shimodaira, K.; Shimizu, Y.; Tsuchiya, N.; Saito, H.; Yanaihara, T.; Okai, T. The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells. Endocr. J. 2002, 49, 371-377.
36. Kurebayashi, J. Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications. Breast Cancer 2000, 7, 124-129.
37. Knupfer, H.; Schmidt, R.; Stanitz, D.; Brauckhoff, M.; Schonfelder, M.; Preiss, R. CYP2C and IL-6 expression in breast cancer. Breast 2004, 13, 28-34.
38. Heinrich, P. C.; Behrmann, I.; Muller-Newen, G.; Schaper, F.; Graeve, L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 1998, 334, 297-314.
39. Trikha, M.; Corringham, R.; Klein, B.; Rossi, J. F. Targeted antiinterleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer Res. 2003, 9, 4653-4665.
40. Banks, R. E.; Forbes, M. A.; Patel, P. M.; Storr, M.; Hallam, S.; Clarke, D.; Novick, D.; Ingham, E.; Bowmer, C.; Southgate, J.; Trejdosiewicz, L. K.; Illingworth, J.; Perren, T. J.; Selby, P. J. Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects. Cytokine 2000, 12, 388-396.
41. Kovacs, E. Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients. Biomed. Pharmacother. 2001, 55, 391-396.
42. Colombo, M. P.; Trinchieri, G. Interleukin-12 in anti-tumour immunity and immunotherapy. Cytokine Growth Factor Rev. 2002, 13, 155-168.
43. Watford, W. T.; Moriguchi, M.; Morinobu, A.; O'Shea, J. J. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. 2003, 14, 361-368.
44. Vitolo, D.; Ciocci, L.; Ferrauti, P.; Tiboni, F.; Cicerone, E.; Gallo, A.; De Vincentiis, M.; Baroni, C. D. Interleukin-12-related cytokine gene expression in carcinomas of the breast, lung, and larynx: a study at tissue level. Cancer Detect. Prev. 2000, 24, 422-434.
45. Wigginton, J. M.; Gruys, E.; Geiselhart, L.; Subleski, J.; Komschlies, K. L.; Park, J. W.; Wiltrout, T. A.; Nagashima, K.; Back, T. C.; Wiltrout, R. H. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J. Clin. Invest. 2001, 108, 51-62.
46. Kornek, G.; Reiner, A.; Sagaster, P.; Stierer, M.; Mayer, A.; Ludwig, H. Effect of interferon alpha-2a on hormone receptor status in patients with advanced breast cancer. Cancer Invest. 1999, 1, 189-194.
47. Miglietta, L.; Repetto, L.; Gardin, G.; Amoroso, D.; Giudici, S.; Naso, C.; Merlini, L.; Queirolo, P.; Campora, E.; Pronzato, P. et al. Tamoxifen and alpha interferon in advanced breast cancer. J. Chemother. 1991, 3, 383-386.
48. Seymour, L.; Bezwoda, W. R. Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators. Br. J. Cancer 1993, 68, 352-356.
49. Macheledt, J. E.; Buzdar, A. U.; Hortobagyi, G. N.; Frye, D. K.; Gutterman, J. U.; Holmes, F. A. Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. Breast Cancer Res. Treat. 1991, 18, 165-170.
50. Ozzello, L.; Habif, D. V.; De Rosa, C. M.; Cantell, K. Cellular events accompanying regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma. Cancer Res. 1992, 52, 4571-4581.
51. Dalla Chiesa, M.; Passalacqua, R.; Michiara, M.; Franciosi, V.; Di Costanzo, F.; Bisagni, G.; Camisa, R.; Buti, S.; Tomasello, G.; Cocconi, G.; Italian Oncology Group for Clinical Research. Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective randomised multicentre trial. Acta Biomed. 2007, 78, 204-209.
52. Sica, G.; Iacopino, F.; Lama, G.; Amadori, D.; Baroni, M.; Lo Sardo, F.; Malacarne, P.; Marchetti, P.; Pellegrini, A.; Zaniboni, A; Robustelli Della Cuna, G. Steroid receptor enhancement by natural interferon-beta in advanced breast cancer. Eur. J. Cancer 1993, 29, 329-333.
53. Buzzi, F.; Brugia, M.; Rossi, G.; Giustini, L.; Scoponi, C.; Sica, G. Combination of beta-interferon and tamoxifen as a new way to overcome clinical resistance to tamoxifen in advanced breast cancer. Anticancer Res. 1992, 12, 869-871.
54. Buzzi, E.; Brugia, M.; Trippa, F.; Rossi, G.; Trivisonne, R.; Giustini, L; Pinaglia, D.; Capparella, V.; Sica, G. Natural interferonbeta and tamoxifen in hormone-resistant patients with advanced breast cancer. Anticancer Res. 1995, 15, 2187-2190.
55. Repetto, L.; Giannessi, P. G.; Campora, E.; Pronzato, P.; Vigani, A.; Naso, C.; Spinelli, I.; Conte, P. F.; Rosso, R. Tamoxifen and interferon-beta for the treatment of metastatic breast cancer. Breast Cancer Res. Treat. 1996, 39, 235-238.
56. Recchia, F.; Rea, S.; De Filippis, S.; Rosselli, M.; Corrao, G.; Gulino, A.; Sica, G. Beta-interferon, retinoids and tamoxifen combination in advanced breast cancer. Clin. Ther. 1998, 149, 203-208.
57. Peretz, T.; Kaplan-DeNour, A.; Baider, L.; Hubert, A.; Stephanos, S.; Barak, V. Combination of interferon and tamoxifen for patients with advanced breast cancer and negative oestrogen receptors. Breast 1997, 6, 190-193.
58. Barak, V.; Kalickman, I.; Nisman, B.; Farbstein, H.; Fridlender, Z. G.; Baider, L.; Kaplan, A.; Stephanos, S.; Peretz, T. Changes in cytokine production of breast cancer patients treated with interferons. Cytokine 1998, 10, 977-983.
59. Rosenberg, S. A. Progress in the development of immunotherapy for the treatment of patients with cancer. J. Intern. Med. 2001, 250, 462-475.
60. Buzio, C.; De Palma, G.; Passalacqua, R.; Potenzoni, D.; Ferrozzi, F.; Cattabiani, M. A.; Manenti, L.; Borghetti, A. Effectiveness of very low doses of immunotherapy in advanced renal cell cancer. Br. J. Cancer 1997, 76, 541-544.
61. Atzpodien, J.; Poliwoda, H.; Kirchner, H. Alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients. Semin. Oncol. 1991, 18, 108-112.
62. Sleijfer, D. T.; Janssen, R. A.; Buter, J.; de Vries, E. G.; Willemse, P. H.; Mulder, N. H. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J. Clin. Oncol. 1992, 10, 1119-1123.
63. Atzpodien, J.; Lopez Hänninen, E.; Kirchner, H.; Bodenstein, H.; Pfreundschuh, M.; Rebmann, U.; Metzner, B.; Illiger, H. J.; Jakse, G.; Niesel, T.; Scholtz, H. J.; Wilhelm, S.; Pielmeier, T.; Zakrzewski, G.; Blum, G.; Beier, J.; Muller, G. W.; Duensing, S.; Anton, P.; Allohff, E.; Jonas, U.; Poliwoda, H. Multiinstitutional home therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J. Clin. Oncol. 1995, 13, 497-501.
64. Lissoni, P.; Barni, S.; Tancini, G.; Ardizzoia, A.; Ricci, G.; Aldeghi, R.; Brivio, F.; Tisi, E.; Rovelli, F.; Rescaldani, R.; Quadro G.; Maestroni, G. A randomised study subcutaneous low-dose interleukin 2 alone vs inteleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br. J. Cancer 1994, 69, 196-199.
65. Atzpodien, J.; Körfer, A.; Franks, C. R.; Poliwoda, H.; Kirchner, H. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 1990, 335, 1509-1512.
66. Israel, L.; Cour, V.; Pihan, I.; Morere, J. F.; Breau, J. L.; Franks, C. R.; Palmer, P.; Loriaux, E. Some theoretical and practical limitations of interleukin-2. Ten cases of advanced breast cancer treated with continuous infusion of IL-2. Cancer Treat. Rev. 1989, 16, 169-171.
67. Stein, R. C.; Malkovska, V.; Morgan, S.; Galazka, A.; Aniszewski, C.; Roy, S. E.; Shearer, R. J.; Marsden, R. A.; Bevan, D.; Gordon-Smith, E. C. et al. The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2. Br. J. Cancer 1991, 63, 275-278.
68. Gravis, G.; Viens, P.; Vey, N.; Blaise, D.; Stoppa, A. M.; Olive, D.; Maraninchi, D. Pilot study of immunotherapy with interleukin-2 after autologous stem cell transplantation in advanced breast cancers. Anticancer Res. 2000, 20, 3987-3991.
69. Guida, M.; Abbate, I.; Casamassima, A.; Musci, M. D.; Latorre, A.; Lorusso, V.; Correale, M.; De Lena, M. Long-term subcutaneous recombinant interleukin-2 as maintenance therapy: biological effects and clinical implications. Cancer Biother. 1995, 10, 195-203.
70. Stewart, A. K.; Lassam, N. J.; Quirt, I. C.; Bailey, D. J.; Rotstein, L. E.; Krajden, M.; Dessureault, S.; Gallinger, S.; Cappe, D.; Wan, Y.; Addison, C. L.; Moen, R. C.; Gauldie, J.; Graham, F. L. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther. 1999, 6, 350-363.
71. Lissoni, P.; Barni, S.; Ardizzoia, A.; Olivini, G.; Brivio, F.; Tisi, E.; Tancini, G.; Characiejus, D.; Kothari, L. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin. J. Biol. Regul. Homeost. Agents 1993, 7, 121-125.
72. rd.; Caligiuri, M.; Montimer, J.; Tkaczuk, K.; Parihar, R.; Schilsky R. L.; Ratain, M. J. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin. Cancer Res. 2002, 8, 3718-3727.
73. Burns, L. J.; Weisdorf, D. J.; DeFor, T. E.; Repka, T. L.; Ogle, K. M.; Hummer, C.; Miller, J. S. Enhancement of the anti-tumour activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer. Exp. Hematol. 2000, 28, 352.
74. Vahdat, L. T.; Cohen, D. J.; Zipin, D.; Lo, K. S.; Donovan, D.; Savage, D.; Tiersten, A.; Nichols, G.; Troxel, A.; Hesdorffer, C. S. Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon-gamma after hig-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer. Bone Marrow Transplant. 2007, 40, 267-272.
75. Meehan, K. R.; Arun, B.; Gehan, E. A.; Berberian, B.; Sulica, V.; Areman, E. M.; Mazumder, A.; Lippman, M. E. Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer. Bone Marrow Transplant. 1999, 23, 667-673.
76. Kimmick, G.; Ratain, M. J.; Berry, D.; Woolf, S.; Norton, L.; Muss, H. B. Cancer and Leukemia Group B (CALGB 9041). Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). Invest. New Drugs 2004, 22, 83-89.
77. Nicolini, A.; Carpi, A. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial. Biomed. Pharmacother. 2005, 59, 253-263.
78. Nicolini, A.; Carpi, A.; Rossi, G. An immunotherapy schedule in endocrine-dependent metastatic breast cancer: correlation between clinical course and immunologic parameters. J. Immunother. 2005, 28, 276-279.
79. Weber, J.; Yang, J. C.; Topalian, S. L.; Parkinson, D. R.; Schwartzentruber, D. S.; Ettinghausen, S. E.; Gunn, H.; Mixon, A.; Kim, H.; Cole, D.; et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J. Clin. Oncol. 1993, 11, 499-506.
80. Parihar, R.; Nadella, P.; Lewis, A.; Jensen, R.; De Hoff, C.; Dierksheide, J. E.; VanBuskirk, A. M.; Magro, C. M.; Young, D. C.; Shapiro, C. L.; Carson, W. E., 3rd. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin. Cancer Res. 2004, 10, 5027-5037.
81. rd; Liang, M. I. Current immunotherapeutic strategies in breast cancer. Surg. Oncol. Clin. N. Am. 2007, 16, 841-860.
82. Nicolini, A.; Carpi, A. Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumour cell biology. Med. Res. Rev. 2009, 29, 436-471.
83. Gallina, G.; Dolcetti, L.; Serafini, P.; De Santo, C.; Marigo, I.; Colombo, M. P.; Basso, G.; Brombacher, F.; Borrello, I.; Zanovello, P.; Bicciato, S.; Bronte, V. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 2006, 116, 2777-2790.
84. Khong, H. T.; Restifo, N. P. Natural selection of tumour variants in the generation of "tumour escape" phenotypes. Nat. Immunol. 2002, 3, 999-1005.
85. Waldner, M.; Schimanski, C. C.; Neurath, M. F. Colon cancer and the immune system: The role of tumour invading T cells. World J. Gastroenterol. 2006, 12, 7233-7238.
86. Schreiber, H.; Wu, T. H.; Nachman, J.; Kast, W. M. Immunodominance and tumour escape. Semin. Cancer Biol. 2002, 12, 25-31.
87. Landowski, T. H.; Qu, N.; Buyuksal, I.; Painter, J. S.; Dalton, W. S. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997, 90, 4266-4270.
88. Gronbaek, K.; Straten, P. T.; Ralfkiaer, E.; Ahrenkiel, V.; Andersen, M. K.; Hansen, N. E.; Zeuthen, J.; Hou-Jensen, K.; Guldberg, P. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998, 92, 3018-3024.
89. Shin, M. S.; Park, W. S.; Kim, S. Y.; Kim, H. S.; Kang, S. J.; Song, K. Y.; Park, J. Y.; Dong, S. M.; Pi, J. H.; Oh, R. R.; Lee, J. Y.; Yoo, N. J.; Lee, S. H. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am. J. Pathol. 1999, 154, 1785-1791.
90. Lenardo, M. J. The molecular regulation of lymphocyte apoptosis. Semin. Immunol. 1997, 1, 1-5.
91. Niehans, G. A.; Brunner, T.; Frizelle, S. P.; Liston, J. C.; Salerno, C. T.; Knapp, D. J.; Green, D. R.; Kratzke, R. A. Human lung carcinomas express Fas ligand. Cancer Res. 1997, 57, 1007-1012.
92. Hahne, M.; Rimoldi, D.; Schroter, M.; Romero, P.; Schreier, M.; French, L. E.; Schneider, P.; Bornand, T.; Fontana, A.; Lienard, D.; Cerottini, J.; Tschopp, J. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumour immune escape. Science 1996, 274, 1363-1366.
93. O'Connell, J.; O'Sullivan, G. C.; Collins, J. K.; Shanahan, F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 1996, 184, 1075-1082.
94. Strand, S.; Hofmann, W. J.; Hug, H.; Muller, M.; Otto, G.; Strand, D.; Mariani, S. M.; Stremmel, W.; Krammer, P. H.; Galle, P. R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumour cells - a mechanism of immune evasion? Nat. Med. 1996, 12, 1361-1366.
95. Zaks, T. Z.; Chappell, D. B.; Rosenberg, S. A.; Restifo, N. P. Fasmediated suicide of tumour-reactive T cells following activation by specific tumour: selective rescue by caspase inhibition. J. Immunol. 1999, 162, 3273-3279.
96. Darnell, J. E. Jr.; Kerr, I. M.; Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264, 1415-1421.
97. Darnell, J. E. Jr. STATs and gene regulation. Science 1997, 277, 1630-1635.
98. Bromberg, J.; Darnell, J. E. Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19, 2468-2473.
99. Bowman, T.; Garcia, R.; Turkson, J.; Jove, R. STATs in oncogenesis. Oncogene 2000, 19, 2474-2488.
100. Yu, H.; Jove, R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 2004, 4, 97-105.
101. Pardoll, D. Does the immune system see tumours as foreign or self? Annu. Rev. Immunol. 2003, 21, 807-839.
102. Andreola, G.; Rivoltini, L.; Castelli, C.; Huber, V.; Perego, P.; Deho, P.; Squarcina, P.; Accornero, P.; Lozupone, F.; Lugini, L.; Stringaro, A.; Molinari, A.; Arancia, G.; Gentile, M.; Parmiani, G.; Fais, S. Induction of lymphocyte apoptosis by tumour cell secretion of FasL-bearing microvesicles. J. Exp. Med. 2002, 195, 1303-1316.
103. Huber, V.; Fais, S.; Iero, M.; Lugini, L.; Canese, P.; Squarcina, P.; Zaccheddu, A.; Colone, M.; Arancia, G.; Gentile, M.; Seregni, E.; Valenti, R.; Ballabio, G.; Belli, F.; Leo, E.; Parmiani, G.; Rivoltini, L. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 2005, 128, 1796-1804.
104. Valenti, R.; Huber, V.; Filipazzi, P.; Pilla, L.; Sovena, G.; Villa, A.; Corbelli, A.; Fais, S.; Parmiani, G.; Rivoltini, L. Human tumour-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res. 2006, 66, 9290-9298.
105. Iero, M.; Valenti, R.; Huber, V.; Filipazzi, P.; Parmiani, G.; Fais, S.; Rivoltini, L. Tumour-released exosomes and their implications in cancer immunity. Cell. Death Differ. 2008, 15, 80-88.
106. DeSimone, P. A.; East, R.; Powell, R. D. Jr. Phagocytic tumour cell activity in oat cellcarcinoma of the lung. Hum. Pathol. 1980, 11, 535-539.
107. Fujii, M.; Ishii, Y.; Wakabayashi, T.; Itoyanagi, N.; Hagiwara, K.; Saito, M.; Takahashi, M. Cytologic diagnosis of male breast cancer with nipple discharge. A case report. Acta Cytol. 1986, 30, 21-24.
108. Kojima, S.; Sekine, H.; Fukui, I.; Ohshima, H. Clinical significance of "cannibalism" in urinary cytology of bladder cancer. Acta Cytol. 1998, 42, 1365-1369.
109. Lugini, L.; Matarrese, P.; Tinari, A.; Lozupone, F.; Federici, C.; Iessi, E.; Gentile, M.; Luciani, F.; Parmiani, G.; Rivoltini, L.; Malorni, W.; Fais, S. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res. 2006, 66, 3629-3638.
110. Saito, A.; Narita, M.; Yokoyama, A.; Watanabe, N.; Tochiki, N.; Satoh, N.; Takizawa, J.; Furukawa, T.; Toba, K.; Fuse, I.; Aizawa, Y.; Shinada, S.; Takahashi, M. Enhancement of anti-tumour cytotoxicity of expanded gammadelta T Cells by stimulation with monocyte-derived dendritic cells. J. Clin. Exp. Hematop. 2007, 47, 61-72.
111. Tokuyama, H.; Hagi, T.; Mattarollo, S. R.; Morley, J.; Wang, Q.; Fai-So, H.; Moriyasu, F.; Nieda, M.; Nicol, A. J. V gamma 9 V delta 2 T cell cytotoxicity against tumour cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab. Int. J. Cancer 2008, 122, 2526-2534.
112. th edition, chapter 5, Masson, Milan, Italian version, 2006, pp. 82-106.
113. Kaplan, M. H.; Sun, Y. L.; Hoey, T.; Grusby, M. J. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 1996, 382, 174-177.
114. Shimoda, K.; van Deursen, J.; Sangster, M. Y.; Sarawar, S. R.; Carson, R. T.; Tripp, R. A.; Chu, C.; Quelle, F. W.; Nosaka, T.; Vignali, D. A.; Doherty, P. C.; Grosveld, G.; Paul, W. E.; Ihle, J. N. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996, 380, 630-633.
115. Adler, A. J.; Marsh, D. W.; Yochum, G. S.; Guzzo, J. L.; Nigam, A.; Nelson, W. G.; Pardoll, D. M. CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J. Exp. Med. 1998, 187, 1555-1564.
116. Vlad, A. M.; Kettel, J. C.; Alajez, N. M.; Carlos, C. A.; Finn, O. J. MUC1 immunobiology: from discovery to clinical applications. Adv. Immunol. 2004, 82, 249-293.
117. Pardoll, D. M.; Topalian, S. L. The role of CD4+ T cell responses in antitumour immunity. Curr. Opin. Immunol. 1998, 10, 588-594.
118. Qin, Z.; Richter, G.; Schuler, T.; Ibe, S.; Cao, X.; Blankenstein, T. B cells inhibit induction of T cell-dependent tumour immunity. Nat. Med. 1998, 4, 627-630.
119. Bronte, V.; Apolloni, E.; Cabrelle, A.; Ronca, R.; Serafini, P.; Zamboni, P.; Restifo, N. P.; Zanovello, P. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000, 96, 3838-3846.
120. Melani, C.; Chiodoni, C.; Forni, G.; Colombo, M. P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003, 102, 2138-2145.
121. Kusmartsev, S.; Gabrilovich, D. I. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J. Leukoc. Biol. 2003, 74, 186-196.
122. Bronte, V.; Serafini, P.; Apolloni, E.; Zanovello, P. Tumour-induced immune dysfunctions caused by myeloid suppressor cells. J. Immunother. 2001, 24, 431-446.
123. Serafini, P.; De Santo, C.; Marigo, I.; Cingarlini, S.; Dolcetti, L.; Gallina, G.; Zanovello, P.; Bronte, V. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 2004, 53, 64-72.
124. Kusmartsev, S.; Gabrilovich, D. I. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol. Immunother. 2002, 51, 293-298.
125. Gabrilovich, D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 2004, 4, 941-952.
126. Baniyash, M. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat. Rev. Immunol. 2004, 4, 675-687.
127. Serafini, P.; Borrello, I.; Bronte, V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 2006, 16, 53-65.
128. Lang, R.; Patel, D.; Morris, J. J.; Rutschman, R. L.; Murray, P. J. Shaping gene expression in activated and resting primary macrophages by IL-10. J. Immunol. 2002, 169, 2253-2263.
129. Lin, C. S.; Ho, H. C.; Chen, K. C.; Lin, G.; Nunes, L.; Lue, T. F. Intracavernosal injection of vascular endothelial growth factor induces nitric oxide synthase isoforms. BJU Int. 2002, 89, 955-960.
130. Serafini, P.; Carbley, R.; Noonan, K. A.; Tan, G.; Bronte, V.; Borrello, I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004, 64, 6337-6343.
131. Cruz, M. T.; Duarte, C. B.; Gonçalo, M.; Figueiredo, A.; Carvalho, A. P.; Lopes, M. C. Granulocyte-macrophage colony-stimulating factor activates the transcription of nuclear factor kappa B and induces the expression of nitric oxide synthase in a skin dendritic cell line. Immunol. Cell. Biol. 2001, 79, 590-596.
132. Dieckmann, D.; Plottner, H.; Berchtold, S.; Berger, T.; Schuler, G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J. Exp. Med. 2001, 193, 1303-1310.
133. Woo, E. Y.; Chu, C. S.; Goletz, T. J.; Schlienger, K.; Yeh, H.; Coukos, G.; Rubin, S. C.; Kaiser, L. R.; June, C. H. Regulatory CD4(+)CD25(+) T cells in tumours from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001, 61, 4766-4772.
134. Sasada, T.; Kimura, M.; Yoshida, Y.; Kanai, M.; Takabayashi, A. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003, 98, 1089-1099.
135. Curotto de Lafaille, M. A.; Lino, A. C.; Kutchukhidze, N.; Lafaille, J. J. CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion. J. Immunol. 2004, 173, 7259-7268.
136. Malek, T. R.; Bayer, A. L. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 2004, 4, 665-674.
137. Terabe, M.; Berzofsky, J. A. Immunoregulatory T cells in tumour immunity. Curr. Opin. Immunol. 2004, 16, 157-162.
138. Ahmadzadeh, M.; Rosenberg, S. A. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006, 107, 2409-2414.
139. Fontenot, J. D.; Rasmussen, J. P.; Gavin, M. A.; Rudensky, A. Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 2005, 6, 1142-1151.
140. Melero, I.; Bach, N.; Chen, L. Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumour antigens. Life Sci. 1997, 60, 2035-2041.
141. Abken, H.; Hombach, A.; Heuser, C.; Kronfeld, K.; Seliger, B. Tuning tumour-specific T-cell activation: a matter of costimulation? Trends Immunol. 2002, 23, 240-245.
142. Nicolini, A.; Campani, D.; Miccoli, P.; Spinelli, C.; Carpi, A.; Menicagli, M.; Ferrari, P.; Gadducci, G.; Rossi, G.; Fini, M.; Giavaresi, G.; Bonazzi, V.; Giardino, R. Vascular endothelial growth factor (VEGF) and other common tissue prognostic indicators in breast cancer: a case-control study. Int. J. Biol. Markers 2004, 4, 275-281.
143. Toi, M.; Taniguchi, T.; Yamamoto, Y.; Kurisaki, T.; Suzuki, H.; Tominaga, T. Clinical significance of the determination of angiogenic factors. Eur. J. Cancer 1996, 14, 2513-2519.
144. Oyama, T.; Ran, S.; Ishida, T.; Nadaf, S.; Kerr, L.; Carbone, D. P.; Gabrilovich, D. I. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J. Immunol. 1998, 160, 1224-1232.
145. Almand, B.; Resser, J. R.; Lindman, B.; Nadaf, S.; Clark, J. I.; Kwon, E. D.; Carbone, D. P.; Gabrilovich, D. I. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 2000, 6, 1755-1766.
146. th edition, chapter 11, Masson: Milan. Italian version, 2006, pp. 249-280.
147. Girolomoni, G.; Ricciardi-Castagnoli, P. Dendritic cells hold promise for immunotherapy. Immunol. Today 1997, 18, 102-104.
148. De Smedt, T.; Van Mechelen, M.; De Becker, G.; Urbain, J.; Leo, O.; Moser, M. Effect of interleukin-10 on dendritic cell maturation and function. Eur. J. Immunol. 1997, 27, 1229-1235.
149. Sharma, S.; Stolina, M.; Lin, Y.; Gardner, B.; Miller, P. W.; Kronenberg, M.; Dubinett, S. M. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J. Immunol. 1999, 163, 5020-5028.
150. Ludewig, B.; Graf, D.; Gelderblom, H. R.; Becker, Y.; Kroczek, R. A.; Pauli, G. Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but strongly enhanced by interleukin-10. Eur. J. Immunol. 1995, 25, 1943-1950.
151. Carbone, E.; Terrazzano, G.; Ruggiero, G.; Zanzi, D.; Ottaiano, A.; Manzo, C.; Karre, K.; Zappacosta, S. Recognition of autologous dendritic cells by human NK cells. Eur. J. Immunol. 1999, 29, 4022-4029.
152. Yue, F. Y.; Dummer, R.; Geertsen, R.; Hofbauer, G.; Laine, E.; Manolio, S.; Burg, G. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int. J. Cancer 1997, 71, 630-637.
153. Huang, M.; Stolina, M.; Sharma, S.; Mao, J. T.; Zhu, L.; Miller, P. W.; Wollman, J.; Herschman, H.; Dubinett, S. M. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine-balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 1998, 58, 1208-1216.
154. Gorsch, S. M.; Memoli, V. A.; Stukel, T. A.; Gold, L. I.; Arrick, B. A. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res. 1992, 52, 6949-6952.
155. Doran, T.; Stuhlmiller, H.; Kim, J. A.; Martin, E. W. Jr.; Triozzi, P. L. Oncogene and cytokine expression of human colorectal tumours responding to immunotherapy. J. Immunother. 1997, 20, 372-376.
156. Chen, W.; Frank, M. E.; Jin, W.; Wahl, S. M. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 2001, 14, 715-725.
157. Fontana, A.; Frei, K.; Bodmer, S; Hofer, E; Schreier, M. H. Palladino, M. A., Jr.; Zinkernagel, R. M. Transforming growth factorbeta inhibits the generation of cytotoxic T cells in virus-infected mice. J. Immunol. 1989, 143, 3230-3234.
158. Morris, D. R.; Kuepfer, C. A.; Ellingsworth, L. R.; Ogawa, Y.; Rabinovitch, P. S. Transforming growth factor-beta blocks proliferation but not early mitogenic signaling events in T-lymphocytes. Exp. Cell. Res. 1989, 185, 529-534.
159. Stoeck, M.; Miescher, S.; MacDonald, H. R.; Von Fliedner, V. Transforming growth factors beta slow down cell-cycle progression in a murine interleukin-2 dependent T-cell line. J. Cell. Physiol. 1989, 141, 65-73.
160. Hoehn, P.; Goedert, S.; Germann, T.; Koelsch, S.; Jin, S.; Palm, N.; Ruede, E.; Schmitt, E. Opposing effects of TGF-beta 2 on the Th1 cell development of naive CD4+ T cells isolated from different mouse strains. J. Immunol. 1995, 155, 3788-3793.
161. Sad, S.; Mosmann, T. R. Single IL-2-secreting precursor CD4 T cell can develop into either Th1 or Th2 cytokine secretion phenotype. J. Immunol. 1994, 153, 3514-3522.
162. Swain, S.L.; Huston, G.; Tonkonogy, S.; Weinberg, A. Transforming growth factor-beta and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J. Immunol. 1991, 147, 2991-3000.
163. Nicolini, A.; Carpi, A.; Ferrari, P.; Berti, P.; Miccoli, P. Microenvironment and cytokines in breast cancer. In Breast cancer: from pathogenesis to potential therapautic modalities. Ed:Transworld Research Network Kerala: India, 2009, chapter 5, pp. 107-163.
164. Lichtner, R. B. Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies. Biomed. Pharmacother. 2003, 57, 447-451.
165. Pietras, R. J. Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast J. 2003, 9, 361-373.
166. Beyer, M.; Schultze, J. L. Regulatory T cells: major players in the tumor microenvironment. Curr. Pharm. Des. 2009, 15, 1879-1892.
167. Hirschhorn-Cymerman, D.; Rizzuto, G. A.; Merghoub, T.; Cohen, A. D.; Avogadri, F.; Lesokhin, A. M.; Weinberg, A. D.; Wolchok, J. D.; Houghton, A. N. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J. Exp. Med. 2009, 206, 1103-1116.
168. Friedl, A.; Jordan, V. C.; Pollak, M. Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. Eur. J. Cancer 1993, 29A(10), 1368-1372.
169. Wolf, D. M.; Gottardis, M. M.; Jordan, V. Tamoxifen-resistant growth. In: Long-term tamoxifen treatment for breast cancer, V Craig Jordan, Edt.; The University of Wisconsin Press: Madison 1994, pp. 199-217.
170. Osborne, C. K. Receptors. In: Breast diseases; Harris, J. R.; Hellman, S.; Henderson, I. C.; Kinne, D. W, Eds. 2nd edition, JB Lippincott Company: Philadelphia, 1995, pp. 301-325.
171. Bezwoda, W. R.; Meyer, K. Effect of alpha-interferon, 17 betaestradiol, and tamoxifen on estrogen receptor concentration and cell cycle kinetics of MCF 7 cells. Cancer Res. 1990, 50, 5387-5391.
172. Cui, X. F.; Imaizumi, T.; Yoshida, H.; Borden, E. C.; Satoh, K. Retinoic acid-inducible gene-I is induced by interferon-gamma and regulates the expression of interferon-gamma stimulated gene 15 in MCF-7 cells. Biochem. Cell. Biol. 2004, 8, 401-405.
173. Pérez- Fidalgo, J. A.; Miranda, J.; Chirivella, I.; Ibánëz, J.; Bermejo, B.; Pons, C.; Melchor, I.; Santaballa, A.; Martínez-Ruiz, F.; Lluch, A.; Salas, D. Impact of mammography screening programme in the breast cancer population of the Region of Valencia (Spain). Clin. Transl. Oncol. 2008, 10, 745-752.
174. Norman, S. A.; Localio, A. R.; Zhou, L.; Weber, A. L.; Coates, R. J.; Malone, K. E.; Bernstein, L.; Marchbanks, P. A.; Liff, J. M.; Lee, N. C.; Nadel, M. R. Benefit of screening mammography in reducing the rate of late-stage breast cancer diagnoses (United States). Cancer Causes Control 2006, 17, 921-929.
175. Pálka, I.; Kelemen, G.; Ormándi, K.; Lázár, G.; Nyáry, T.; Thurzó, L.; Kahán, Z. Tumor characteristics in screen-detected and symptomatic breast cancers. Pathol. Oncol. Res. 2008, 14, 161-167.
176. Simes, R. J.; Coates, A. S. Patient preference for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J. Natl. Cancer Inst. Monogr. 2001, 30, 146-152.
177. Cianfrocca, M.; Gradishar, W. J. Controversies in the therapy of early stage breast cancer. Oncologist 2005, 10, 766-779.
178. Angeli, F.; Koumakis, G.; Chen, M. C.; Kumar, S.; Delinassios, J. G. Role of stromal fibroblasts in cancer: promoting or impeding? Tumour Biol. 2009, 30, 109-120.
179. Miller, L. J.; Kurtzman, S. H.; Anderson, K.; Wang, Y.; Stankus, M.; Renna, M.; Lindquist, R.; Barrows, G.; Kreutzer, D. L. Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest. 2000, 18, 293-302.
180. Liu, L.; Gudas, L. J. Retinoic acid induces expression of the interleukin-1beta gene in cultured normal human mammary epithelial cells and in human breast carcinoma lines. J. Cell. Physiol. 2002, 193, 244-252.
181. Iacopetta, B.; Grieu, F.; Joseph, D. The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. Br. J. Cancer 2004, 90, 419-422.
182. Benoy, I. H.; Salgado, R.; Van Dam, P.; Geboers, K.; Van Marck, E.; Scharpe, S.; Vermeulen, P. B.; Dirix, L. Y. Increased serum inteleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin. Cancer Res. 2004, 10, 7157-7162.
183. Niwa, Y.; Akamatsu, H.; Niwa, H.; Sumi, H.; Ozaki, Y.; Abe, A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin. Cancer Res. 2001, 7, 285-289.
184. Meng, L.; Zhou, J.; Sasano, H.; Suzuki, T.; Zeitoun, K. M.; Bulun, S. E. Tumour necrosis factor alpha and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiated by selectively down-regulating CCAAT/ enhancer binding protein alpha and peroximose proliferator-activated receptor gamma: Mechanism of desmoplastic reaction. Cancer Res. 2001, 61, 2250-2255.
185. Newton, C. J.; Buric, R.; Trapp, T.; Brockmeier, S.; Pagotto, U.; Stalla, G. K. The unlinganded estrogen receptor (ER) transduces growth factor signals. J. Steroid Biochem. Mol. Biol. 1994, 48, 481-486.
186. Lee, A. V.; Weng, C. N.; Jackson, J. G.; Yee, D. Activation of estrogen receptor-mediated gene transcription by IGF.I in human breast cancer cells. J. Endocrinol. 1997, 152, 39-47.
187. Stewart, A. J.; Johnson, M. D.; May, F. E.; Westley, B. R. Role of insulin-like growth factors and the type I onsulin-like growth factopr receptor in the estrogen-stimulated proliferation of human breast cancer cells. J. Biol. Chem. 1990, 265, 21172-21178.
188. Jechlinger, M.; Sommer, A.; Moriggl, R.; Seither, P.; Kraut, N.; Capodiecci, P.; Donovan, M.; Cordon-Cardo, C.; Beug, H.; Grunert, S. Autocrine PDGFR signaling promotes mammary cancer metastasis. J. Clin. Invest. 2006, 116, 1561-1570.
189. Carvalho, I.; Milanezi, F.; Martins, A.; Reis, R. M.; Schmitt, F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res. 2005, 7, R788-R795.
190. Bos, R.; van Diest, P. J.; de Jong, J. S.; van der Grope, P.; van der Valk, P.; van der Wall, E. Hypoxiainducible factor-1alpha is associated with angiogenesis and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 2005, 46, 31-36.
191. Mattila, M. M.; Tarkkonen, K. M.; Seppanen, J. A.; Ruohola, J. K.; Valve, E. M.; Harkonen, P. L. Androgen and fibroblast growth factor 8 (FGF8) downregulation of thrombospondin 1 (TSP1) in mouse breast cancer cells. Mol. Cell Endocrinol. 2006, 253, 36-43.
192. Vandermoere, F.; El Yazidi-Belkoura, I.; Adriaenssens, E.; Lemoine, J.; Hondermarck, H. The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and IhappaB kinase-beta in breast cancer cells. Oncogene 2005, 24, 5482-5491.
193. Seeger, H.; Wallwiener, D.; Mueck, A. O. Influence of stroma-derived growth factor on the estradiol-stimulated proliferation of human breast cells. Eur. J. Gynaecol. Oncol. 2004, 25, 175-177.
194. Coffelt, S. B.; Hughes, R.; Lewis, C. E. Tumor-associated macrophages: Effectors of angiogenesis and tumor progression. Biochim. Biophys. Acta 2009, 1796, 11-18.